Associate Director, Business Development and Strategic Alliances @ (February 2020 - April 2021)
Associate Director, Clinical Program and Alliance Management @ (April 2016 - January 2020)
Associate Director, Clinical Program and Alliance Management, Genoptix, a Novartis Company @ (April 2016 - March 2017)
Senior Project Manager, Genoptix, a Novartis Company @ (March 2013 - March 2016)
Field Applications Scientist and Associate Product Manager @ (August 2012 - March 2013)
Research Associate Iii, Bioscience Division @ (May 2010 - August 2012)
Postdoctoral Research Scientist @ (June 2008 - May 2010)
Scientific Associate @ (January 2009 - January 2010)
Procurement and Operations @ (January 2004 - January 2010)
PHD Candidate @ (September 2001 - June 2008)
Research Associate @ Ucsd Health Promotion Services (January 2000 - January 2001)
Research Internship @ (January 1999 - January 2000)
Irene Ch'En Education
UC San Diego
Doctor of Philosophy (Biology, Immunology)
2001-2008
UC San Diego
Bachelor of Science (Biochemistry, Biology)
1996-2000
Irene Ch'En Skills
Assay Development
Biotechnology
Cancer
Cell
Cell Biology
Cell Culture
Clinical Trials
Communication
Competitive Analysis
Creative Problem Solving
Critical Thinking
DNA
Easily Adaptable
External Liaison
FDA
Flow Cytometry
GMP
Genetics
Genomics
Immunoassays
Immunology
Leadership
Life Sciences
Lifesciences
Mass Spectrometry
Molecular Biology
Pharmaceutical Industry
Problem Solving
Protein Chemistry
Proteomics
Science
Validation
Irene Ch'En Summary
Irene Ch'En, based in San Diego, CA, US, is currently a Director, Alliance Management at BeiGene. Irene Ch'En brings experience from previous roles at Navigate Biopharma Services, Inc. and Novartis Oncology. Irene Ch'En holds a 2001 - 2008 Doctor of Philosophy in Biology, Immunology @ UC San Diego. With a robust skill set that includes Assay Development, Biotechnology, Cancer, Cell, Cell Biology and more. Irene Ch'En has 1 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Irene Ch'En?
Find contact details for 700 million professionals.